The mRNA-1345 RSV vaccine candidate - Moderna Inc. bets on older adults

The mRNA-1345 RSV vaccine candidate from Moderna Inc. sits in a cooled steel tray, a clear solution in small glass vials that catch the fluorescent light of the clinical site. Nurses in white sneakers roll the cart down a quiet corridor, while Stéphane Bancel, Moderna’s CEO, tracks trial updates on his tablet from Boston.

Single-shot RSV protection focus

Moderna developed mRNA-1345 as an investigational mRNA vaccine against respiratory syncytial virus (RSV) in adults aged 60 and older. The vaccine encodes stabilized prefusion F glycoproteins from both RSV A and RSV B strains, aiming to trigger robust neutralizing antibodies after a single dose. In the pivotal Phase 3 trial, called ConquerRSV, the company evaluated a 50 µg dose of mRNA-1345 in roughly 37,000 participants worldwide. A key readout has been the reduction in RSV-associated lower respiratory tract disease, a condition that often starts as a harmless cough and becomes dangerous for older adults.

According to Moderna, interim Phase 3 data for mRNA-1345 showed a vaccine efficacy of about 83.7 percent against RSV-associated lower respiratory tract disease with at least two symptoms in older adults. This efficacy estimate was based on adjudicated cases in the pre-specified primary endpoint window and compared to placebo, underlining the potential of mRNA technology beyond COVID-19. Regulatory submissions for mRNA-1345 are underway or planned in multiple regions, including the United States, Europe, and other markets, as the company positions the product for seasonal use before RSV peaks each winter.

Trial design and safety profile

In ConquerRSV, participants were randomized to receive either a single IM injection of mRNA-1345 or placebo before the expected RSV season, then followed for RSV-associated outcomes. The trial was event-driven, using laboratory-confirmed RSV infection combined with clinical symptom criteria to define lower respiratory tract disease. Moderna designed the protocol to capture not only medically attended events but also milder RSV cases, seeking a detailed picture of how well the vaccine works across severity levels. As trial staff wheeled portable spirometry devices into exam rooms, data monitors tracked every cough, fever, and oxygen saturation drop.

Safety data for mRNA-1345 showed a profile consistent with other adult vaccines, with most adverse events being mild to moderate and transient, such as injection-site pain, fatigue, and headache. Serious adverse events judged related to the vaccine were rare, with no new safety signals reported in interim analyses. The company highlighted these safety findings in its regulatory filings and investor presentations, pointing to the tolerability of a single pre-season dose in an older population that often has comorbidities like COPD or heart failure. During investigator meetings, physicians like Dr. Jacqueline Miller, Moderna’s head of development for infectious diseases, reviewed safety tables slide by slide.

Market positioning against pharma rivals

RSV vaccines for older adults have quickly become a competitive field, with established pharmaceutical companies like GSK and Pfizer already marketing protein-based RSV vaccines. Moderna is entering this arena with an mRNA platform, betting that a single pre-season shot using mRNA-1345 can match or exceed protein-based rivals on efficacy while offering manufacturing flexibility. The company leverages experience from its COVID-19 mRNA vaccines, re-using parts of its supply chain and fill-finish infrastructure to bring mRNA-1345 to market on a seasonal schedule. In slides shown to investors, bar charts compare Moderna’s RSV efficacy to competing products, even though cross-trial comparisons have limitations.

Market analysts estimate that the global RSV vaccine market in older adults could reach several billion dollars annually over the next decade, especially as awareness of RSV’s burden rises. For payers and health systems, a key factor will be comparative effectiveness, but also price and ease of deployment, particularly in community pharmacies and primary care settings where older adults receive vaccines. A single-dose schedule for mRNA-1345 aligns with existing workflows for flu and COVID-19 boosters, allowing combination visits in the fall season. Pharmacists can store the vials at recommended temperatures and administer the vaccine alongside other shots, minimizing extra visits for high-risk patients.

Real-world logistics and regulatory journey

Before mRNA-1345 can be widely used, regulators such as the U.S. Food and Drug Administration and the European Medicines Agency must review efficacy, safety, and manufacturing data. Moderna has already submitted or prepared dossiers, including detailed chemistry, manufacturing, and controls documentation for the mRNA construct and lipid nanoparticle formulation. Inspectors have visited Moderna’s facilities and contract manufacturing sites, walking past stainless-steel bioreactors humming softly and checking batch records stored in secure digital systems. The company aims for labeling that clearly defines the target population, dosage, and schedule with straightforward language for clinicians.

Logistically, Moderna must secure cold-chain distribution and coordinate deliveries with large pharmacy chains, hospitals, and clinics for each RSV season. That means planning production months in advance to align with local RSV epidemiology, which differs by region but generally peaks in colder months. Moderna’s operations teams, under the leadership of executives like Juan Andres, have experience from scaling COVID-19 vaccines and are now applying similar planning to RSV. They monitor inventory by lot number, track shipment temperatures, and maintain contingency stocks in case of regional surges or supply disruptions, such as transportation strikes or extreme weather events.

Clinical need among older adults

RSV can cause serious illness in older adults, especially those with underlying cardiopulmonary diseases or weakened immune systems. Symptoms may start as a mild upper respiratory infection but can progress to bronchitis or pneumonia, leading to hospitalizations and even death. In waiting rooms, clinicians often see older patients with wheezing, chest tightness, and shortness of breath, symptoms that might be attributed to flu or COVID-19 but are sometimes RSV on closer lab testing. This clinical overlap makes prevention through vaccination attractive; fewer infections mean fewer diagnostic puzzles in crowded seasons.

Moderna positions mRNA-1345 as a tool to reduce RSV-associated lower respiratory tract disease and potentially prevent hospitalizations in this vulnerable group. In its trial data, the company has highlighted not only overall efficacy but also consistency across subgroups, such as those with chronic conditions or different age brackets above 60. Physicians like Dr. Miller point out in presentations that even moderate reductions in RSV cases can have sizable impact on healthcare system burden, especially when combined with other respiratory vaccines. For patients, the experience may be simple: one appointment, one injection, and a hopefully milder RSV season.

Pipeline synergies and combination prospects

Beyond a stand-alone RSV shot, Moderna is working on combination respiratory vaccines that could integrate RSV, influenza, and COVID-19 antigens into a single injection in the future. Such combinations, still investigational, would build on the mRNA-1345 backbone or a closely related RSV construct, aiming for broad respiratory coverage with one seasonal visit. Development teams at Moderna’s Cambridge headquarters sketch trial designs on whiteboards, imagining arms comparing stand-alone RSV, dual combinations, and triple combinations across different age groups. Regulatory pathways for combinations will be more complex, but they could amplify market impact if they succeed.

For now, mRNA-1345 remains a focused RSV candidate in older adults, but its clinical data and manufacturing characteristics inform broader platform decisions. Choices about lipid nanoparticle composition, mRNA length, and antigen design in mRNA-1345 generate insights applicable to other programs, including vaccines targeting cytomegalovirus or other pathogens. The company’s R&D leadership, including President Stephen Hoge, has spoken publicly about how each advanced candidate is both a product and a source of platform learning. That iterative cycle means that success or setbacks with mRNA-1345 will resonate across Moderna’s pipeline, not just in RSV.

Context and Moderna stock

For retail investors and consumers, mRNA-1345 is one piece of a larger Moderna portfolio that includes COVID-19 boosters, cancer vaccines, and other infectious disease candidates. The RSV program contributes to diversification away from a single-virus dependence, introducing a recurring seasonal revenue stream if regulators clear the product and uptake is strong. As RSV vaccines compete on efficacy, safety, and practical deployment, Moderna’s positioning with mRNA-1345 will influence how its broader vaccine business is perceived by markets. On Nasdaq, Moderna Inc. stock (ISIN US60770K1079) reflects investor expectations for this RSV candidate alongside the rest of the pipeline.